[go: up one dir, main page]

WO2012079878A3 - Hla-binding peptides derived from prostate-associated antigenic molecules and methods of use thereof - Google Patents

Hla-binding peptides derived from prostate-associated antigenic molecules and methods of use thereof Download PDF

Info

Publication number
WO2012079878A3
WO2012079878A3 PCT/EP2011/070024 EP2011070024W WO2012079878A3 WO 2012079878 A3 WO2012079878 A3 WO 2012079878A3 EP 2011070024 W EP2011070024 W EP 2011070024W WO 2012079878 A3 WO2012079878 A3 WO 2012079878A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
prostate
hla
binding peptides
peptides derived
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2011/070024
Other languages
French (fr)
Other versions
WO2012079878A2 (en
Inventor
Toni Weinschenk
Peter Lewandrowski
Hans-Georg Rammensee
Stefan Stevanovic
Cécile GOUTTEFANGEAS
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immatics Biotechnologies GmbH
Original Assignee
Immatics Biotechnologies GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2010/069675 external-priority patent/WO2011073215A2/en
Priority to EA201300693A priority Critical patent/EA201300693A1/en
Priority to JP2013543601A priority patent/JP6032853B2/en
Priority to AU2011344652A priority patent/AU2011344652B2/en
Priority to CA2821582A priority patent/CA2821582A1/en
Priority to MX2013006758A priority patent/MX2013006758A/en
Priority to SG2013045737A priority patent/SG191154A1/en
Priority to NZ60991611A priority patent/NZ609916A/en
Priority to CN201180059274.2A priority patent/CN103547283A/en
Priority to EP11782613.1A priority patent/EP2651434A2/en
Application filed by Immatics Biotechnologies GmbH filed Critical Immatics Biotechnologies GmbH
Priority to US13/993,291 priority patent/US9023804B2/en
Priority to KR1020137018147A priority patent/KR20130126671A/en
Publication of WO2012079878A2 publication Critical patent/WO2012079878A2/en
Publication of WO2012079878A3 publication Critical patent/WO2012079878A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4274—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; Prostatic acid phosphatase [PAP]; Prostate-specific G-protein-coupled receptor [PSGR]
    • A61K40/4276—Prostate specific membrane antigen [PSMA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Methods and compositions for immunotherapeutic treatment of prostate cancer are disclosed. More specifically methods of treating patients with prostate cancer comprising administering compositions comprising HLA-binding peptides derived from prostate-associated antigenic molecules, either with or without immunological adjuvants, are disclosed.
PCT/EP2011/070024 2004-08-19 2011-11-14 Hla-binding peptides derived from prostate-associated antigenic molecules and methods of use thereof Ceased WO2012079878A2 (en)

Priority Applications (11)

Application Number Priority Date Filing Date Title
KR1020137018147A KR20130126671A (en) 2010-12-14 2011-11-14 Hla-binding peptides derived from prostate-associated antigenic molecules and methods of use thereof
NZ60991611A NZ609916A (en) 2010-12-14 2011-11-14 Hla-binding peptides derived from prostate-associated antigenic molecules and methods of use thereof
AU2011344652A AU2011344652B2 (en) 2010-12-14 2011-11-14 HLA-binding peptides derived from prostate-associated antigenic molecules and methods of use thereof
CA2821582A CA2821582A1 (en) 2010-12-14 2011-11-14 Hla-binding peptides derived from prostate-associated antigenic molecules and methods of use thereof
MX2013006758A MX2013006758A (en) 2010-12-14 2011-11-14 Hla-binding peptides derived from prostate-associated antigenic molecules and methods of use thereof.
SG2013045737A SG191154A1 (en) 2010-12-14 2011-11-14 Hla-binding peptides derived from prostate-associated antigenic molecules and methods of use thereof
CN201180059274.2A CN103547283A (en) 2010-12-14 2011-11-14 HLA-binding peptides derived from prostate-associated antigenic molecules and methods of use thereof
EA201300693A EA201300693A1 (en) 2010-12-14 2011-11-14 FORMED FROM THE MOLECULES OF ANTIGENES ASSOCIATED WITH THE PRESTATIVE IRON, PEPTIDES, CONNECTING THE HLA MOLECULES AND METHODS OF THEIR APPLICATION
EP11782613.1A EP2651434A2 (en) 2010-12-14 2011-11-14 Hla-binding peptides derived from prostate-associated antigenic molecules and methods of use thereof
JP2013543601A JP6032853B2 (en) 2010-12-14 2011-11-14 HLA-binding peptide derived from prostate-related antigen molecule and method of use thereof
US13/993,291 US9023804B2 (en) 2004-08-19 2011-11-14 HLA-binding peptides derived from prostate-associated antigenic molecules and methods of use thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EPPCT/EP2010/069675 2010-12-14
PCT/EP2010/069675 WO2011073215A2 (en) 2009-12-14 2010-12-14 Hla-binding peptides derived from prostate-associated antigenic molecules and methods of use thereof

Publications (2)

Publication Number Publication Date
WO2012079878A2 WO2012079878A2 (en) 2012-06-21
WO2012079878A3 true WO2012079878A3 (en) 2012-08-09

Family

ID=44983532

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2011/070024 Ceased WO2012079878A2 (en) 2004-08-19 2011-11-14 Hla-binding peptides derived from prostate-associated antigenic molecules and methods of use thereof

Country Status (9)

Country Link
JP (1) JP6032853B2 (en)
KR (1) KR20130126671A (en)
CN (1) CN103547283A (en)
AU (1) AU2011344652B2 (en)
CA (1) CA2821582A1 (en)
MX (1) MX2013006758A (en)
NZ (1) NZ609916A (en)
SG (1) SG191154A1 (en)
WO (1) WO2012079878A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2689145C2 (en) * 2014-04-16 2019-05-24 Биокон Лтд. Stable protein preparations containing molar excess of sorbitol

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102013012432A1 (en) * 2013-07-29 2015-01-29 Eberhard Karls Universität Tübingen Medizinische Fakultät Immunotherapy of prostate cancer
CA2989347A1 (en) * 2015-06-12 2016-12-15 Lentigen Technology, Inc. Method to treat cancer with engineered t-cells
GB201513921D0 (en) * 2015-08-05 2015-09-23 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
GB201521746D0 (en) * 2015-12-10 2016-01-27 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against CLL and other cancers
GB201602918D0 (en) * 2016-02-19 2016-04-06 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against NHL and other cancers
GB201603987D0 (en) 2016-03-08 2016-04-20 Immatics Biotechnologies Gmbh Uterine cancer treatments
KR102379955B1 (en) 2016-12-08 2022-03-29 이매틱스 바이오테크놀로지스 게엠베하 Mating Enhanced T Cell Receptor
DE102016123893A1 (en) 2016-12-08 2018-06-14 Immatics Biotechnologies Gmbh T cell receptors with improved binding
EP3580561B1 (en) * 2017-02-12 2023-11-01 BioNTech US Inc. Hla-based methods and compositions and uses thereof
KR102215578B1 (en) * 2019-03-28 2021-02-15 한국과학기술연구원 Human leukocyte antigen specific binding peptides and uses thereof

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001045728A2 (en) * 1999-12-21 2001-06-28 Epimmune Inc. Inducing cellular immune responses to prostate cancer antigens using peptide and nucleic acid compositions
WO2001075067A2 (en) * 2000-03-31 2001-10-11 Hyseq, Inc. Novel nucleic acids and polypeptides
US20020081680A1 (en) * 2000-04-17 2002-06-27 Jiangchun Xu Compositions and methods for the therapy and diagnosis of prostate cancer
WO2003070889A2 (en) * 2002-02-19 2003-08-28 Idec Pharmaceuticals Corporation Prostate specific genes and the use thereof in design or therapeutics
WO2004016643A2 (en) * 2002-08-16 2004-02-26 Yeda Research And Development Co. Ltd. Tumor associated antigen, peptides thereof, and use of same as anti-tumor vaccines
WO2004053075A2 (en) * 2002-12-05 2004-06-24 Diadexus, Inc. Compositions, splice variants and methods relating to breast specific genes and proteins
WO2005033265A2 (en) * 2003-04-25 2005-04-14 Epimmune Inc. Optimized multi-epitope constructs and uses thereof
WO2006023598A2 (en) * 2004-08-19 2006-03-02 University Of Maryland, Baltimore Prostate-specific antigen-derived mhc class ii-restricted peptides and their use in vaccines to treat or prevent prostate cancer
EP2111867A1 (en) * 2008-04-24 2009-10-28 Immatics Biotechnologies GmbH Novel formulations of tumour-associated peptides binding to human leukocyte antigen (HLA) class I or II molecules for vaccines
EP2119726A1 (en) * 2008-05-14 2009-11-18 Immatics Biotechnologies GmbH Novel and powerful MHC-class II peptides derived from survivin and neurocan
EP2172211A1 (en) * 2008-10-01 2010-04-07 Immatics Biotechnologies GmbH Composition of tumor-associated peptides and related anti-cancer vaccine for the treatment of glioblastoma (GBM) and other cancers

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA725596A (en) 1960-08-26 1966-01-11 J. Wretlind Arvid Method of preparing intravenously injectable fat emulsions free from side reactions or complications
US4897445A (en) 1986-06-27 1990-01-30 The Administrators Of The Tulane Educational Fund Method for synthesizing a peptide containing a non-peptide bond
AUPM322393A0 (en) 1993-12-24 1994-01-27 Austin Research Institute, The Mucin carbohydrate compounds and their use in immunotherapy
US5849589A (en) 1996-03-11 1998-12-15 Duke University Culturing monocytes with IL-4, TNF-α and GM-CSF TO induce differentiation to dendric cells
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
US7892559B2 (en) 2002-01-30 2011-02-22 Survac Aps Survivin-derived peptides and use thereof
ES2319286T3 (en) 2004-10-02 2009-05-06 Immatics Biotechnologies Gmbh IMMUNOGEN EPITHOPES OF LYMPHOCYTES T COLLABORATORS OF HUMAN TUMOR ANTIGENS AND USE OF SUCH EPITHOPES IN IMMUNOTHERAPEUTIC METHODS.
ES2341802T3 (en) 2005-09-05 2010-06-28 Immatics Biotechnologies Gmbh PEPTIDES ASSOCIATED WITH UNITED TUMORS PROMISCUALLY TO MOLECULES OF THE HUMAN LEUKOCYTE ANTIGEN (HLA) CLASS II.

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001045728A2 (en) * 1999-12-21 2001-06-28 Epimmune Inc. Inducing cellular immune responses to prostate cancer antigens using peptide and nucleic acid compositions
WO2001075067A2 (en) * 2000-03-31 2001-10-11 Hyseq, Inc. Novel nucleic acids and polypeptides
US20020081680A1 (en) * 2000-04-17 2002-06-27 Jiangchun Xu Compositions and methods for the therapy and diagnosis of prostate cancer
WO2003070889A2 (en) * 2002-02-19 2003-08-28 Idec Pharmaceuticals Corporation Prostate specific genes and the use thereof in design or therapeutics
WO2004016643A2 (en) * 2002-08-16 2004-02-26 Yeda Research And Development Co. Ltd. Tumor associated antigen, peptides thereof, and use of same as anti-tumor vaccines
WO2004053075A2 (en) * 2002-12-05 2004-06-24 Diadexus, Inc. Compositions, splice variants and methods relating to breast specific genes and proteins
WO2005033265A2 (en) * 2003-04-25 2005-04-14 Epimmune Inc. Optimized multi-epitope constructs and uses thereof
WO2006023598A2 (en) * 2004-08-19 2006-03-02 University Of Maryland, Baltimore Prostate-specific antigen-derived mhc class ii-restricted peptides and their use in vaccines to treat or prevent prostate cancer
EP2111867A1 (en) * 2008-04-24 2009-10-28 Immatics Biotechnologies GmbH Novel formulations of tumour-associated peptides binding to human leukocyte antigen (HLA) class I or II molecules for vaccines
EP2119726A1 (en) * 2008-05-14 2009-11-18 Immatics Biotechnologies GmbH Novel and powerful MHC-class II peptides derived from survivin and neurocan
EP2172211A1 (en) * 2008-10-01 2010-04-07 Immatics Biotechnologies GmbH Composition of tumor-associated peptides and related anti-cancer vaccine for the treatment of glioblastoma (GBM) and other cancers

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
KIESSLING ET AL: "Advances in Specific Immunotherapy for Prostate Cancer", EUROPEAN UROLOGY, ELSEVIER BV, NL, vol. 53, no. 4, 26 November 2007 (2007-11-26), pages 694 - 708, XP022495956, ISSN: 0302-2838 *
QIN H ET AL: "Specific antitumor immune response induced by a novel DNA vaccine composed of multiple CTL and T helper cell epitopes of prostate cancer associated antigens", IMMUNOLOGY LETTERS, ELSEVIER BV, NL, vol. 99, no. 1, 15 June 2005 (2005-06-15), pages 85 - 93, XP004891413, ISSN: 0165-2478, DOI: DOI:10.1016/J.IMLET.2005.01.006 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2689145C2 (en) * 2014-04-16 2019-05-24 Биокон Лтд. Stable protein preparations containing molar excess of sorbitol

Also Published As

Publication number Publication date
JP6032853B2 (en) 2016-11-30
CN103547283A (en) 2014-01-29
AU2011344652B2 (en) 2015-11-19
NZ609916A (en) 2015-03-27
MX2013006758A (en) 2013-08-01
CA2821582A1 (en) 2012-06-21
KR20130126671A (en) 2013-11-20
SG191154A1 (en) 2013-07-31
WO2012079878A2 (en) 2012-06-21
JP2014502961A (en) 2014-02-06
AU2011344652A1 (en) 2013-05-23

Similar Documents

Publication Publication Date Title
WO2011073215A3 (en) Hla-binding peptides derived from prostate-associated antigenic molecules and methods of use thereof
WO2012079878A3 (en) Hla-binding peptides derived from prostate-associated antigenic molecules and methods of use thereof
NZ603271A (en) Anti-erbb3 antibodies
WO2012006634A3 (en) Prostate specific antigen (psa) peptide therapy
WO2012177595A9 (en) Compositions and methods for the therapy and diagnosis of cancer
GB201009222D0 (en) Improved cancer therapy based on tumour associated antigens derived from cyclin D1
WO2012170776A3 (en) Methods of determining a patient's prognosis for recurrence of prostate cancer and/or determining a course of treatment for prostate cancer following a radical prostatectomy
AU2011338383A8 (en) Treatment of HER2-positive cancer with paclitaxel and trastuzumab-MCC-DM1
WO2011143656A3 (en) Compositions and methods of identifying tumor specific neoantigens
NZ631197A (en) Anti sez6 antibodies and methods of use
SG10201903119QA (en) Polypeptide vaccine
SG194701A1 (en) Anti-cd40 antibodies and methods of use
NZ707086A (en) Anti-cd40 antibodies and methods of use
NZ606195A (en) Methods and compositions for liver cancer therapy
WO2010003520A3 (en) Anti-tumor immunotherapy
MY158992A (en) Forms of rifaximin and uses thereof
MX347734B (en) S100a4 antibodies and therapeutic uses thereof.
MX2011010955A (en) Adjuvant cancer therapy.
IL225262A0 (en) Methods and preparations for the treatment of lung cancer
HK1199290A1 (en) Methods and compositions for the treatment and diagnosis of breast cancer
WO2015200828A8 (en) Conjugates for immunotherapy
MX349948B (en) Immunogenic proteins and compositions for the treatment and prevention of streptococcus agalactiae.
WO2015067755A3 (en) Novel methods and antibodies for treating coagulapathy
WO2012170513A3 (en) He4 based therapy for malignant disease
MX2012013875A (en) Peripheral blood sparc antibodies and uses thereof.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11782613

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2011344652

Country of ref document: AU

Date of ref document: 20111114

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2013543601

Country of ref document: JP

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2821582

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: MX/A/2013/006758

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: A201305361

Country of ref document: UA

ENP Entry into the national phase

Ref document number: 20137018147

Country of ref document: KR

Kind code of ref document: A

REEP Request for entry into the european phase

Ref document number: 2011782613

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2011782613

Country of ref document: EP

Ref document number: 201300693

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: 13993291

Country of ref document: US

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112013014771

Country of ref document: BR

REG Reference to national code

Ref country code: BR

Ref legal event code: B01E

Ref document number: 112013014771

Country of ref document: BR

ENPW Started to enter national phase and was withdrawn or failed for other reasons

Ref document number: 112013014771

Country of ref document: BR